Nature Reviews Drug Discovery

Article	Citations
Vaccine exposes tumours to immune cell attack	1554
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	943
A specific biomarker for insoluble tau	711
Targeting tumour-associated bacteria	709
Neutralizing Zika virus	615
A new path to targeted protein degradation?	615
The improving benefit–risk balance of phase I cancer trials	547
FDA approves a c-MET-targeted ADC for lung cancer	513
Tumour cells get a dendritic cell makeover	441
Glucose-sensitive insulin protects against hypoglycaemia	425
Promoting tissue repair after heart attack	423
Hypoimmune iPSCs escape immune detection	397
Lipid nanoparticle ferries therapeutic mRNA to the placenta	387
FDA new drug approvals in Q1 2023	384
Apolipoprotein L2 inhibitor mitigates fibrosis	379
AI serves up target and inhibitor for lung fibrosis	376
Chemical engineering of CRISPR–Cas systems for therapeutic application	373
New antibiotic for urinary tract infections nabs FDA approval	371
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	364
Target identification and assessment in the era of AI	335
mRNA vaccines for infectious diseases — advances, challenges and opportunities	313
Anti-tau antibody stumbles in phase II Alzheimer trial	306
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	294
Targeting the Hippo pathway in cancer	288
Small-molecule discovery through DNA-encoded libraries	286

FDA approves second TTR stabilizer for cardiac amyloidosis	265
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	253
Targeting drug-resistant glioblastoma	252
Degrading cell-free DNA to prevent recurrent stroke	251
2022 FDA approvals	230
Increasing the potency of T cell therapies	225
Small molecule improves muscle function in myasthenia gravis	219
Pushing both sides of the drug pricing aisle	214
Host-directed antiviral blocks SARS-CoV-2 entry	211
TCR-engineered T cells get personal	198
2025’s FDA approvals by regulatory designations	196
Inhibiting ASGR1 boosts cholesterol removal	195
FDA new drug approvals in Q2 2023	191
Rewired proteostasis in KRAS inhibitor resistance	188
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	179
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	177
An allosteric site on cereblon	175
A renaissance in targeting the PI3K/AKT/mTOR pathway	174
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	157
Mimicking the health benefits of exercise	156
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	149
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	146
R&D re-balancing act	145
The significance of blockbusters in the pharmaceutical industry	139
Base editors hit the clinic	138
Phenotypic drug discovery: recent successes, lessons learned and new directions	138
Combating antimicrobial resistance in malaria, HIV and tuberculosis	136
Roads and detours for CAR T cell therapy in autoimmune diseases	134
Amylin takes another shot at the obesity prize	133
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	126
The antibody–drug conjugate landscape	124
Antibody–drug conjugates come of age in oncology	122
Multi-TACs target solid tumours	120
Immunology on the brain	118
Gut metabolite mediates nerve repair	116
Reducing IL-2 toxicity	113
Agonist antibody lowers blood pressure	113
Monkeypox mRNA vaccine protects mice and macaques	112
Neglected tropical diseases go global	107
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	107
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	104
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	102
Designing G-protein-selective allosteric modulators	100
Targeting the ECM in melanoma	98
Redirecting mast cells for antigen-specific cancer immunotherapy	97
LRRK2-targeted Parkinson disease drug advances into phase III	96
Ribosome inhibitor combats bacterial drug resistance	95
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	94
Anti-IL-11 antibody shows anti-ageing properties	88
The European Innovation Network as a hub for medicines innovation in Europe	87

Frameworks for transformational breakthroughs in RNA-based medicines	86
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	84
Avidity in antibody effector functions and biotherapeutic drug design	78
Engineered parasite delivers proteins to the brain	78
Engineering a compact genome-editing tool	73
Upcoming market catalysts in Q4 2023	72
Delivering genome editing tools to primary cells	72
A rush of CRISPR to the lungs	71
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	67
The non-small-cell lung cancer drug market	67
Broader horizons for cereblon glue degraders	66
Trends in the development of cellular and gene therapy in China	65
Promoting efferocytosis heals diabetic wounds	63
Accelerating precision oncology by converging pragmatic trials and real-world evidence	62
Publisher Correction: Roflumilast	57
RNA structure guides antiviral ASO design	56
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	56
Betting on β-catenin inhibitors in oncology	56
MYC in cancer: from undruggable target to clinical trials	55
Covalent inhibitor engages oncogenic AKT kinase	55
Investigating the origins of recent pharmaceutical innovation	54
AAV-based in vivo gene therapy for neurological disorders	53
Three-step cures for autoimmune diseases?	52
Targeting protein disorder: the next hurdle in drug discovery	52
A bacteria-derived oral tumour vaccine	50
Upcoming market catalysts in Q4 2024	47
V-ATPase inhibitor targets Ras-mutant cancers	47
Designing novel macrocyclic drugs	45
Towards a broad-spectrum antiviral agent	45
Can large, simple trials bring drug developers back to common diseases?	45
Glue-based KRAS inhibitors make their debut cancer trial mark	44
Calico, Alphabet’s anti-ageing play, goes it alone	44
Neurotensin receptor modulator safely tackles pain	44
Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out	44
De novo design of macrocycles	41
Cartilage regeneration for osteoarthritis	41
Understanding LAG3 immune checkpoint function	40
2023 FDA approvals: unprecedented volume at moderate value	39
FDA approves cell-sheet-based gene therapy for severe skin disease	39
Microbial ‘dark matter’ yields new antibiotic	39
Hinge modifier approach opens door to drugging HECT E3 ligases	38
PPAR agonists provide new treatment options for inflammatory liver disease	38
RNA delivery heats up cold tumours	38
The evolution of the obesity drug market	37
A new drug target for NRAS(Q61) mutant-expressing cancers	35
The case for cell-penetrating peptides	34
Analysis of China-to-West pharmaceutical licensing deals in 2024	34
Novel strategies to manage CAR-T cell toxicity	33
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	33
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	33
RNA chemistry and therapeutics	32
A faster route to antidepressant activity	31
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	31
Synthetic cytokine circuit targets solid tumours	30
Transcription reprogramming to enhance CAR-T cell function	29
Designing a novel synthetic receptor	28
Designing closure-stabilizing integrin inhibitors	28
A step closer to in vivo editing of haematopoietic stem cells	28
FDA approves 21-valent pneumococcal vaccine	27
PD1 × VEGF blocking bispecifics for cancer draw big backing	26
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	25
FDA approves PI3Kα inhibitor that does double duty as a degrader	25
Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	25
Improving efficacy of ASO therapy in SMA	25
CAR T cells take to the airways	24
Unmet needs in vaccine development	24
Designing insulin receptor agonists	23
Top product forecasts for 2025	23
Genome-editing medicinal products: the EMA perspective	22
Sequential immunotherapy: towards cures for autoimmunity	22
FDA approves first factor XIIa inhibitor, for hereditary angioedema	22
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	22
Enhancing CAR-T cell efficacy through IFN ablation	22
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	21
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	21
Safety considerations for cereblon-recruiting targeted protein degraders	21
Novel schizophrenia therapy filed for FDA approval	21
Targeting galectin-driven regulatory circuits in cancer and fibrosis	21
In vivo CAR T cells move into clinical trials	21
Drugging the efferocytosis process: concepts and opportunities	21

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	21
Understanding the effects of antibiotic combinations	20
Treating cannabis use disorder	20
Acyl-lysine reader inhibitor blocks AML progression	20
Synthesizing portimines	20
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	20
RNAi-based drug design: considerations and future directions	20
Brain glucose mediates amphotericin B tolerance	19
Stalled molecular motor inhibits tumour growth	19
Epigenetic editor silences prion protein	19
Open-science drug discovery for COVID-19	19
Bacteria tag tumours for CAR-T cell attack	19
FDA approves GLP-1 pill for obesity	18
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	18
Neurons give metastatic cells a push	18
Building on the momentum of N-of-1 base editor therapies for rare diseases	18
CRISPR activation tackles neurodevelopmental disorders	18
Trends in the drug target landscape for autoimmune diseases	18
ASO targets DNA repair protein to combat Huntington disease	18
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	18
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	18
Kinase inhibitors trigger target degradation	17
Dose-finding and optimization in drug development for rare diseases	17
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	17
The KRAS crowd targets its next cancer mutations	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	16
Trustworthy AI for safe medicines	16
Advanced technologies for the development of infectious disease vaccines	16
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	16
Alnylam scores big pharma support for angiotensinogen silencer	15
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	15
Thinking outside the box: non-canonical targets in multiple sclerosis	15
Gene editing addresses antithrombin deficiency	15
Insights into new approach methodology innovation: an EMA perspective	15
Understanding immunomodulatory antibody agonism	14
Understanding sphingosine-1-phosphate transport	14
Ramping up mitochondrial DNA replication	14
FDA releases tissue-agnostic cancer drug draft guidance	14
Targeting ALDH1B1 in colorectal cancer	14
A new antibiotic for A. baumannii	14
Setting GPCRs free	13
Soluble Notch agonists drive T cell production	13
FDA approves first claudin-18.2-targeted antibody for gastric cancer	13
Membrane transporters in drug development and as determinants of precision medicine	13
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	13
Targeting cytokine networks in neuroinflammatory diseases	13
Macrophages as tools and targets in cancer therapy	13
Phosphatase inhibitor drives anticancer immune responses	12
FDA approves first chikungunya vaccine	12
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	12
FDA approves first two drugs for rare Niemann–Pick disease	12
The renal cell carcinoma drug market	12
Upcoming market catalysts in Q3 2023	12
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	12
Antibody drug conjugate combats inflammation	11
Targeting expanded trinucleotide repeats	11
Mapping cysteine ligandability	11
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	11
Chromatin-targeted drug discovery at “a very special moment”	11
Two-pronged approach for macular degeneration	11
2022 FDA approval number dips: a COVID-19 hangover?	10
Developing an IKZF2 glue degrader	10
Roche buys MASH contender for up to US$3.5 billion	10
FDA approves PI3K inhibitor for a rare immune disorder	10
Repurposing beta-blockers in breast cancer	10
Understanding semaglutide action in the brain	10
BacPROTAC to treat tuberculosis	10
RNF41 reverses liver fibrosis	10
Novel drug targets in 2023	9
Boosting CAR T cell efficacy	9
Targeting ephrin signalling in sepsis	9
Top product forecasts for 2026	9
The potential of innovative trial design for efficiently evaluating repurposed drugs	9
New route to target RAS	9
FDA approves BTK inhibitor for chronic hives	9
Lipid flippase inhibitor tackles drug-resistant fungi	8
In vivo CAR T purchase spree continues with Lilly deal worth up to US$7 billion	8
Fibrosis: cross-organ biology and pathways to development of innovative drugs	8
New therapeutic candidate for Chagas disease	8
Deuterium in drug discovery: progress, opportunities and challenges	8
Trikines rewire STAT signalling	8
Advances in the treatment of systemic lupus erythematosus	8
2023 FDA approvals	8
Targeting immunogenic cell stress and death for cancer therapy	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
How multispecific molecules are transforming pharmacotherapy	8
AhR inhibition promotes axon regeneration	8
Opportunities for mitochondrial disease gene therapy	8
Pfizer’s small-molecule antiviral misses on COVID prevention	8
Oncolytic virus drought continues, as Replimune fails to secure FDA cancer approval	7
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines	7
Targeting glial lipid metabolism to tackle neurodegeneration	7
Antipsychotic displays dual GPCR binding mode	7
COVID vaccines: “We flew the aeroplane while we were still building it”	7
Novel antimalarial passes key phase III test	7